10 莫德纳下调新冠疫苗销售预测

Moderna has downgraded the sales forecasts for its Covid-19 vaccine this year, blaming delays in international shipping and temporary issues related to manufacturing capacity.

莫德纳下调了其新冠疫苗的今年全年销售预测，并将其归咎于国际运输延误和与制造产能相关的暂时问题。

The US biotech said on Thursday it expects product sales of $15bn to $18bn in 2021, down from an earlier estimate of $20bn in August. The company now expects to deliver 700m to 800m doses this year, compared to earlier estimates of between 800m to 1bn.

这家美国生物技术公司周四表示，预计2021年产品销售额为150亿至180亿美元，低于早先在8月估计的200亿美元。该公司现在预计今年将交付7亿至8亿剂，而此前的估计为8亿至10亿剂。

Moderna shares fell as much as 11 per cent in premarket trading after the disappointing guidance. Consensus estimates from analysts had forecast full-year sales of $19.8bn.

发布这一令人失望的指引后，莫德纳股价在盘前交易时段下跌11%。此前分析师们对该公司全年销售额的共识估计为198亿美元。

“Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market,” Moderna said in a statement.

“影响产量的关键变量包括国际发运和出口的交货时间延长，可能会将一部分交付推迟至2022年初完成；扩大灌封能力以及增加向市场投放产品的工作所造成的暂时影响。”莫德纳在一份声明中表示。